Device Trial Radar · NCT03041467
IN.PACT™ AV Access IDE Study
Last checked: Nov 20, 2026Latest source record: May 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
330
Actual
Start
Apr 25, 2017
Primary completion
Dec 6, 2018
Study completion May 5, 2023
Sponsor
- Lead sponsor
- Medtronic EndovascularPublic (MDT)
- Sponsor type
- Industry
- First posted
- Feb 2, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of the IN.PACT™ AV Access Drug Coated Balloon (DCB) compared to percutaneous transluminal angioplasty (PTA) for treatment of subjects presenting with de novo or non-stented restenotic obstructive lesion of native arteriovenous dialysis fistulae (AVF) in the upper extremity.
Conditions
- Arteriovenous Fistula Stenosis
- Arteriovenous Fistula Occlusion
- Arteriovenous Fistula
- Fistula
Interventions
IN.PACT AV DCBDevice
IN.PACT™ AV Paclitaxel-Coated Percutaneous Transluminal Angioplasty (PTA) Balloon
Standard Balloon AngioplastyDevice
Standard PTA Balloon
Primary outcomes
What the sponsor says the trial is designed to measure.
- Target Lesion Primary Patency Rate Through 6 MonthsTime frame: 6 Months Post-Procedure
- Primary Safety Endpoint - Serious Adverse Event RateTime frame: 30 days post procedure
Locations
29 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham (UAB) Hospital
Birmingham, Alabama
SKI Vascular Center
Tempe, Arizona
Capital Nephrology Medical Group
Sacramento, California
26 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.